2015


To access this material please log in or register

Register Authorize
2015/№6

New oral anticoagulants in cardiologic practice: The issue of switching drugs and strategies for its solution

Malinova L. I.1, Podbolotov R. A.1, Denisova T. P.2
1 – Federal State Budgetary Institution, “Saratov Research Institute of Cardiology” at the RF Ministry of Health Care, Chernyshevskogo 141, Saratov 410028
2 – State Budgetary Educational Institution of Higher Professional Education, “V. I. Razumovsky Saratov State Medical University” of the RF Ministry of Health Care, Bolshaya Kazachjya 112, Saratov 410012

Keywords: anticoagulants, treatment, cardiovascular diseases

DOI: 10.18087/rhj.2015.6.2120

Background. Long-term anticoagulant support, which has become possible only after launching of oral anticoagulants (AC), is needed for prevention of thrombotic and thromboembolic complications of cardiovascular diseases (CVD). Aim. To evaluate state-of-the-art in switching from indirect oral AC (IDAC) to new oral AC (dabigatran etexilate, rivaroxaban, apixaban, edoxaban). Materials and methods. We have analyzed information from 425 sources indexed in bibliographic open-access databases using a modified PRISMA algorithm. Results. 36 publications issued between 2011 and 2015 were selected. Mean impact factor of journals where these reports were published was 4.637. Seven sources were indexes in eLibrary and 29 – in PubMed. Most of the publications were original studies (13) and reviews (13), none of which was systematic. Three reports focused on results of clinical studies; 3 reports used data of a registry, and one report described a clinical case. Conclusion. The performed analysis revealed a considerable shortage of evidence basis for switching from IDAC to new AC.
  1. Бокерия Л. А., Ковалев С. А., Филатов А. Г., Ковалёв А. С. Лечение фибрилляции предсердий: данные рандомизированных исследований. Вестник экспериментальной и клинической хирургии. 2012; V (2):447–62.
  2. Карпов Ю. А. Апиксабан: новые возможности профилактики осложнений у больных с фибрилляцией предсердий. Атмосфера. Новости кардиологии. 2013;4:2–8.
  3. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013 Jul;34 (27):2094–106.
  4. Новикова Н. А., Регушевская Д. В. Варфарин: место в современной антикоагулянтной терапии. Русский медицинский журнал. 2014;22 (2):147–51.
  5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365 (10):883–91.
  6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361 (12):1139–51.
  7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365 (11):981–92.
  8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369 (22):2093–104.
  9. Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V, Schreier T, Gobelt M et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015 Apr;17 (4):530–8.
  10. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999 Feb 1;59 (3):635–46.
  11. Burghaus R, Coboeken K, Gaub T, Niederalt C, Sensse A, Siegmund HU et al. Computational investigation of potential dosing sche­dules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor. Front Physiol. 2014 Nov 7;5:417.
  12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6 (7):e1000097.
  13. Moher D, Altman DG, Liberati A, Tetzlaff J. PRISMA statement. Epidemiology. 2011 Jan;22 (1):128.
  14. Сердечная Е. В., Татарский Б. А. Новые пероральные антикоагулянты для пациентов с фибрилляцией предсердий. Эффективная фармакотерапия. 2014;25:54–60.
  15. Татарский Б. А., Казеннова Н. В. Возможный выбор новых пероральных антикоагулянтов при неклапанной фибрилляции предсердий: обзор мета-анализов. Кардиология. 2015;55 (3):97–105.
  16. Широков Е. А. Идеология современной системы профилактики инсульта. Клиническая медицина. 2014;92 (3):5–10.
  17. Шубик Ю. В. Антитромботическая терапия при фибрилляции предсердий. Вестник аритмологии. 2014;75:50–75.
  18. Patel AA, Ogden K, Mody SH, Bookhart B. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. J Med Econ. 2015 May;18 (5):323–32.
  19. Ahmad Y, Lip GY. Warfarin for stroke prevention in atrial fibrillation: time to switch? Int J Clin Pract. 2013 Jul;67 (7):603–5.
  20. Werth S, Breslin T, NiAinle F, Beyer-Westendorf J. Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). Am J Cardiovasc Drugs. 2015 Aug;15 (4):235–42.
  21. Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost. 2015 Feb;113 (2):231–46.
  22. Caldeira D, Costa J, Ferreira JJ, Pinto FJ. Thromboembolic risk in the initiation, switch and interruption / re-initiation of oral anticoagulants: do newcomers improve outcomes? Insights from a meta-analysis of RCTs. Int J Cardiol. 2014 Nov 15;177 (1):117–9.
  23. Barcellona D, Luzza M, Battino N, Fenu L, Marongiu F. The criteria of the Italian Federation of Thrombosis Centres on DOACs: a “real world” application in nonvalvular atrial fibrillation patients already on vitamin K antagonist. Intern Emerg Med. 2015 Mar;10 (2):157–63.
  24. Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G et al. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol. 2013 Aug 1;112 (3):387–9.
  25. Elewa HF, DeRemer CE, Keller K, Gujral J, Joshua TV. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis. 2014 Jul;38 (1):115–20.
  26. Attaya S, Bornstein T, Ronquillo N, Volgman R, Braun LT, Trohman R, Volgman A. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther. 2012 Nov;19 (6):432–5.
  27. Zolfaghari S, Harenberg J, Frolich L, Weiss C, Wehling M, Wild P et al. Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients' preference. Semin Thromb Hemost. 2015 Mar;41 (2):166–77.
  28. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015 Jun;113 (6):1247–57.
  29. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Rollig D, Schreier T et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol. 2014 Oct;78 (4):908–17.
  30. Eikelboom JW, Vanassche T, Connolly SJ. Switching patients from blinded study drug to warfarin at the end of the ENGAGE AF-TIMI 48 trial: setting a new standard. J Am Coll Cardiol. 2014 Aug 12;64 (6):585–7.
  31. Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2013 Apr;75 (4):966–78.
  32. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace. 2014 Oct;16 (10):1443–9.
  33. Sawaya FJ, Musallam KM, Arnaout S, Rabah A, Sawaya J. Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely. Int J Cardiol. 2012 Jan 26;154 (2):e27–8.
  34. Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med. 2014 Dec;127 (12):1179–85.
  35. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care. 2013 Sep;19 (9):e325–32.
  36. Shaughnessy AF. Increased GI Bleeding After Switch from Warfarin to Dabigatran. Am Fam Physician. 2015 May 1;91 (9):648.
  37. Abuzeid W, Al-Lawati H, Fam N. Acute myocardial infarction after switching from warfarin to dabigatran. Oman Med J. 2015 Jan;30 (1):55–8.
  38. Brais C, Larochelle J, Turgeon M, Tousignant A, Blais L, Perreault S et al. Patterns of oral anticoagulants use in atrial fibrillation. J Popul Ther Clin Pharmacol. 2015;22 (1):e90–5.
  39. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011 Nov;106 (5):868–76.
  40. Siegmund HU, Burghaus R, Kubitza D, Coboeken K. Contribution of rivaroxaban to the international normalized ratio when swit­ching to warfarin for anticoagulation as determined by simulation studies. Br J Clin Pharmacol. 2015 Jun;79 (6):959–66.
Malinova L. I., Podbolotov R . A., Denisova T. P. New oral anticoagulants in cardiologic practice: The issue of switching drugs and strategies for its solution. Russian Heart Journal. 2015;14 (6):362–368

To access this material please log in or register

Register Authorize
Ru En